Roel Klein Wolterink

Research activity per year

Fingerprint

Dive into the research topics where Roel Klein Wolterink is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

4 Article
2 (Systematic) Review article

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody
Gong, Y., Germeraad, W. T. V., Zhang, X., Wu, N., Li, B., Janssen, L., He, Z., Gijbels, M. J. J., Wu, B., Gijsbers, B. L. M. G., Olieslagers, T. I., Bos, G. M. J., Zheng, L. & Klein Wolterink, R. G. J., 7 Aug 2024, In: Molecular Therapy. 32, 8, p. 2711-2727 17 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
Pellagra: de vergeten groente onder de dermatosen
Translated title of the contribution: Pellagra: The forgotten entity among dermatosesLogger, J. G. M., Klein Wolterink, R. G. J., de Vries, H. J. C. & Henquet, C. J. M., 1 Jan 2023, In: Nederlands Tijdschrift voor Dermatologie en Venereologie. 33, 1, p. 37-40 4 p.
Research output: Contribution to journal › Article › Academic
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Wolterink, R. G. J. K., Wang, J. X., Bos, G. M. J. & Germeraad, W. T. V., 1 May 2021, In: Journal of Hematology & Oncology. 14, 1, 35 p., 73.
Research output: Contribution to journal › (Systematic) Review article › peer-review

Open Access
Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity
Gong, Y., Klein Wolterink, R. G. J., Gulaia, V., Cloosen, S., Ehlers, F. A. I., Wieten, L., Graus, Y. F., Bos, G. M. J. & Germeraad, W. T. V., Jun 2021, In: Cancers. 13, 11, 19 p., 2579.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor
Gong, Y., Wolterink, R. G. J. K., Janssen, I., Groot, A. J., Bos, G. M. J. & Germeraad, W. T. V., 12 Jun 2020, In: Molecular Therapy - Methods and Clinical Development. 17, p. 634-646 13 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Roel Klein Wolterink

Fingerprint

Research output

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Pellagra: de vergeten groente onder de dermatosen

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity

Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor